|
Showing 1 - 6 of
6 matches in All Departments
Volume 42 of "Progress in Drug Research" contains seven reviews and
the various indexes which facilitate its use and establish the con
nection with the previous volumes. The articles in this volume deal
with organization and management of drug research; luteinizing hor
mone regulators; natural products as anticancer agents; flavonoids
and their pharmacological activity; serenics in the control of
mental disturbances; Transfer Factor and its application and with
Transfer Factor in malignancy. In the 34 years that "Progress in
Drug Research" has existed, the Edi tor has enjoyed the valuable
help and advice of many colleagues. Readers, the authors of the
reviews, and last but not least, the review ers have all
contributed greatly to the success of this series. Although the
comments received so far have generally been favorable, it is
nevertheless necessary to analyze and to reassess the current
position and the future direction of such a review series. So far,
it has been the Editors intention to help disseminate informa tion
on the vast domain of drug research, and to provide the reader with
a tool with which to keep abreast of the latest developments and
trends. The reviews in PDR are useful to the non-specialists, who
can obtain an overview of a particular field of drug research in a
rela tively short time."
Founded in 1959 by its current Editor, the series has moved from
its initial focus on medicinal chemistry to a much wider scope.
Today it encompasses all fields concerned with the development of
new therapeutic drugs and the elucidation of their mechanisms of
action, reflecting the increasingly complex nature of modern drug
research. Invited authors present their biological, chemical,
biochemical, physiological, immunological, pharmaceutical,
toxicological, pharmacological and clinical expertise in carefully
written reviews and provide the newcomer and the specialist alike
with an up-to-date comprehensive list of prime references. Each
volume of Progress in Drug Research contains fully
cross-referencing indices which link the books together, forming a
virtually encyclopaedic work. The series thus serves as an
important, time-saving source of information for researchers
concerned with drug research and all those who need to keep abreast
of the many recent developments in the quest for new and better
medicines.
S. Ren and E.J. Lien: CaCo-2 cell permeability vs human
gastrointestinal absorption: QSPR analysis.- J.C.G. Halford and
J.E. Blundell: Pharmacology of appetite suppression.- B. Olivier,
W. Soudijn and I. van Wijngaarden: Serotonin, dopamine and
norepinephrine transporters in the central nervous system and their
inhibitors.- D. Poyner, H. Cox, M. Bushfield, J.M. Treherne and
M.K. Demetrikopoulos: Neuropeptides in drug research.- M. Kumari
and M.K. Ticku: Regulation of NMDA receptors by ethanol.- H.
Horikoshi, T. Hashimoto and T. Fujiwara: Troglitazone and emerging
glitazones: new avenues for potential therapeutic benefits beyond
glycemic control.- Rosamund C. Smith and Simon J. Rhodes:
Applications of developmental biology to medicine and animal
agriculture
Volume 43 of "Progress in Drug Research" contains five reviews and
the various indexes which facilitate its use and establish the
connection with the previous volumes. The articles in this volume
deal with high cholesterol blood levels and other dyslipidemias;
search of ideal antihypertensive drugs; the natural PQlyamines and
the immune system; biologically active quinazolones and with
production and action of interferons. In the 35 years the PDR has
existed, the Editor has enjoyed the valuable help and advice of
many colleagues. Readers, the authors of the reviews, and last but
not least, the reviewers have all contributed greatly to the
success of this series. Although the comments received so far have
generally been favorable, it is nevertheless necessary to analyze
and to reassess the current position and the future direction of
such a review series. So far, it has been the Editors intention to
help disseminate information on the vast domain of drug research,
and to provide the reader with a tool with which to keep abreast of
the latest developments and trends. The reviews in PDR are useful
to the non-specialist, who can obtain an overview of a particular
field of drug research in a relatively short time. The specialist
readers of PDR will appreciate the reviews' comprehensive
bibliographies, and, in addition, they may even get fresh impulses
for their own research. Finally, the readers can use the 43 volumes
of PDR as an encyclopedic source of information.
In the treatment of infections caused by rapidly mutating viruses
like human immunodeficiency virus (HIV), combination therapy with
multiple drugs act ing by different mechanisms offers several
advantages over monotherapy. It may provide: synergistic effect,
possible reduction of dosages and side-effects, and reduction of
the chance of drug resistance. In the past few years, hun dreds of
HIV protease inhibitors have been synthesized and tested in order
to overcome the limitations of reverse transcriptase inhibitors
like zidovudine and others. In this review, emphasis is placed on
the development of HIV pro tease inhibitors as antiviral agents
against HIY, and structure-activity rela tionship analysis of
saquinavir and related compounds. Limitations of some protease
inhibitors and ways to overcome the shortcomings are presented.
Among these many protease inhibitors five have been marketed during
1995-1999. They are saquinavir, ritonavir, indinavir, nelfinavir
and ampre navir. Their different structural features, important
physicochemical, phar macokinetic and clinical profiles are
presented in a table form for easy com parison. It is hoped that in
the future new drugs based on additional mech anisms can be
developed for the treatment of AIDS. Contents 4 1 Introduction
....................................................................
. HIV protease as a target for chemotherapy
................................... . 2 5 Design of protease
inhibitors .................................................. . 3 5
Basis of rational design of HIV protease inhibitors
........................... . 3.1 5 New development of HIV protease
inhibitors ................................ . 6 3.2 HIV protease
inhibitors on the market ........................................ .
20 4 20 4.1 SAR of saquinavir and related compounds
.................................... ."
Founded in 1959 by its current Editor, the series has moved from
its initial focus on medicinal chemistry to a much wider scope.
Today it encompasses all fields concerned with the development of
new therapeutic drugs and the elucidation of their mechanisms of
action, reflecting the increasingly complex nature of modern drug
research. Invited authors present their biological, chemical,
biochemical, physiological, immunological, pharmaceutical,
toxicological, pharmacological and clinical expertise in carefully
written reviews and provide the newcomer and the specialist alike
with an up-to-date comprehensive list of prime references. Each
volume of Progress in Drug Research contains fully
cross-referencing indices which link the books together, forming a
virtually encyclopaedic work. The series thus serves as an
important, time-saving source of information for researchers
concerned with drug research and all those who need to keep abreast
of the many recent developments in the quest for new and better
medicines.
|
|